The aim of this study was to determine whether there is a relation between serum prohepcidin level and disease activity of rheumatoid arthritis (RA) and systemic lupus erythematous (SLE), and to discover whether it has a role in the anaemia of chronic disease occurring in RA and SLE patients.
Patients and methods
This study was carried out on 30 patients suffering from RA and 30 patients suffering from SLE. In addition, 20 healthy volunteers were recruited as controls. All patients and controls were subjected to full history taking, thorough clinical examination, locomotor system examination, assessment of the disease activity in RA patients using the Disease Activity Score-28, assessment of the disease activity in SLE patients using Systemic Lupus Erythematous Disease Activity Index, laboratory investigations, including complete blood count, erythrocyte sedimentation rate (ESR), rheumatoid factor and C-reactive protein (CRP), and measurement of serum prohepcidin levels by the enzyme-linked immunosorbant assay.
The mean serum prohepcidin concentration was 395.2±551.4ng/ml in RA patients, whereas it was 381.5±88.07 in SLE patients and 121.4±11.1ng/ml in healthy volunteers. The prohepcidin concentration correlated with the rheumatoid factor, Creactive protein, ESR, disease duration, morning stiffness, tender joint count, swollen joint count, Larsen score, haemoglobin level and Disease Activity Score-28 in RA patients. There were positive significant correlations between the mean serum prohepcidin concentration and platelets number, haemoglobin level and ESR in SLE patients and insignificant correlations between the mean serum prohepcidin concentration and Systemic Lupus Erythematous Disease Activity Index.
Prohepcidin could be considered as a useful marker for RA, but not for SLE. Prohepcidin may have a role in anaemia of chronic disease occurring in RA and SLE.
Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med 2007; 120:936–939.
Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119–129.
Mehmet D, Sivrikya A, Celik G, Vatansev H. The role of prohepcidin and hepcidin in anemia associated with systemic lupus erythematous. World Appl Sci J 2011; 3:2032–2036.
Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100:3376–3381.
DemiragMD, Haznedaroglu S, Sancak B, Konca C, Gulbahar O, Ozturk MA, et al. Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern Med 2009; 48:421–426.
Oustamanolakis P, Koutroubakis IE, Messaritakis I, Malliaraki N, Sfiridaki A, Kouroumalis EA. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur JGastroenterolHepatol 2011; 23:262–268.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BKet al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113:1271–1276.
Ganz T. Hepcidin – a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005; 18:171–182.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569–2581.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.
Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52:2625–2635.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35:630–640.
Rovetta G, Bianchi G, Monteforte P, Buffrini L, Ghirardo G. Automated diagnosis and characterization of Lyme disease using neutral network analysis. J Rheumatol 1995; 22:571–572.
Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33:167–239.
Roitt IM, Brostoff J, Male DK. Immunology. New York; London, Churchill Livingstone; Gower Medical Publishing 1985; 7.1–7.14.
Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med 2014; 20:408–414.
Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus – old and new. Autoimmun Rev 2013; 12:784–1784.
Theurl I, Schroll A, Nairz M, Seifert M, Theurl M, Sonnweber T, et al. Pathways for the regulation of hepcidin expression in anemia of chronic disease andiron deficiency anemia in vivo. Haematologica 2011; 96:1761–1769.
Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 2005; 106:2196–2199.
Mecklenburg I, Reznik D, Fasler-Kan E, Beglinger C. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis 2014; 8:1569–1752.
Kemna E, Pickkers P, Nemeth E, Vander Hoeven H, Swinkels D. Timecourse analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106:1864–1866.
Dagli M, Yilmaz M, Sivrikaya A, Ozturk B. Serum prohepcidin and hepcidin levels in patients with ankylosing spondylitis: a prospective study. World Appl Sci J 2013; 28:1281–1285.
Paköz ZB, ÇekiçC, Arabul M, SarıtaşYüksel E, İpek S, Vatansever S, et al. An evaluation of the correlation betweenhepcidin serumlevels and disease activity in inflammatory bowel disease. Gastroenterol Res Pract 2015; 2015:1–4.
Koca SS, Isik A, Ustundag B, Metin K, Aksoy K. Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus. Inflammation 2008; 31:146–153.
Kim HR, Kim KW, Yoon SJ, Kim SH, Lee SH. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J Korean Med Sci 2010; 25:348–352.
Adriana S, Valeanu M, Bolosiu HD, Craciun AM. Evaluation of serum hepcidin variations in patients with rheumatoid arthritis according to anemia profile and its correlation with disease activity. Rev Romana Med Lab 2013; 21:17–27.
Means RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003; 2:116–121.
Roe MA, Spinks C, Heath AL, Harvey LJ, Foxall R, Wimperis J, et al. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. Br J Nutr 2007; 97:544–549.
Nagy J, Lakner L, Poór VS, Pandur E, Mózsik G, Miseta A, et al. Serum prohepcidin levels in chronic inflammatory bowel diseases. J Crohns Colitis 2010; 4:649–653.
Emerah A, Abbas SF, Pasha HF. Serum prohepcidin concentrations in rheumatoid arthritis and its relation to disease activity. Egypt Rheumatol Rehabil 2014; 41:130–134.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms.
About this article
Cite this article
Ganeb, S.S., Hamad, G.A.E., El-Tanawy, R.M. et al. Correlations between Serum prohepcidin level disease activity in rheumatoid arthritis and systemic lupus erythematous. Egypt Rheumatol Rehabil 43, 102–107 (2016). https://doi.org/10.4103/1110-161X.189827
- rheumatoid arthritis
- systemic lupus erythematous